Evidence for an influence of overall treatment time on radiotherapeutic - Outcome in different tumor entities;Fur welche tumorentitaten ist ein einfluss der gesamtbehandlungszeit auf die ergebnisse der strahlentherapie evident?

Strahlentherapie und Onkologie

Volumn 176, Issue 10, 2000, Pages 462-465

  Stuschke, Martin ^a   Marnitz, Simone ^b   Wurm, Reinhard ^b   Budach, Volker ^b  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Acceleration; Meta analysis; Randomized trials; Repopulation

Indexed keywords

ARTICLE; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; TIME; TREATMENT OUTCOME; COMPARATIVE STUDY; HEAD AND NECK TUMOR; LUNG TUMOR; MORTALITY; RADIATION DOSE; REVIEW; SMALL CELL CARCINOMA; THEORETICAL MODEL; TUMOR RECURRENCE;

CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; LUNG NEOPLASMS; META-ANALYSIS; MODELS, THEORETICAL; NEOPLASM RECURRENCE, LOCAL; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS;

EID: 0033814310     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: 10.1007/pl00002311     Document Type: Article

References (12)

1. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: Final report of an Australian multi-centre trial
2. Time-dependent tumour repopulation factors in linear-quadratic equations - Implications for treatment strategies
3. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer
4. Continuous hyperfractionated accelerated radiotherapy and mitomycin C in head and neck cancer
5. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: Preliminary results of RTOG 9003
6. Accelerated fractionation compared to conventional fractionation improves loco-regional control in the radiotherapy of advanced head and neck cancers: Results of the EORTC 22851 randomized trial
7. A randomised trial of accelerated versus conventional radiotherapy in head and neck cancer
8. Conventional radiotherapy as primary treatment of squamous cell carcinoma of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week - Report from the DAHANCA 7 trial
9. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: Mature data from the randomised multicentre trial
10. Is 7 fractions in 7 days better than conventional 5 fraction a week irradiation of head and neck cancer?
11. Fractionation sensitivities and dose-control relations of head and neck carcinomas: Analysis of the randomised hyperfractionation trials
12. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide